Arcturus Therapeutics

Arcturus Therapeutics is a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based therapeutics
Arcturus Therapeutics has built a multicultural team, based in San Diego, CA, USA
We have an exciting COVID-19 vaccine candidate that we hope will make a positive difference in the pandemic
See our team describe what it means for them to help get a vaccine to protect people around the world-no matter where you are from
A
S
L
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/JoePayne_LanguageProficiency_V3_1.mp4?time=1652891374
arabic
(عربى)
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/MaherA_LanguageProficiency_V3_1.mp4?time=1652891374
chinese
(中文)
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/thumbnail_BelleBao.jpg?time=1652891374,https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/BelleBao_LanguageProficiency__V3_1.mp4?time=1652891374
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/thumbnail_HowardYu.jpg?time=1652891374,https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/HowardYu_LanguageProficiency_V3_1.mp4?time=1652891374
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/thumbnail_YurongGuo.jpg?time=1652891374,https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/YurongGuo_LanguageProficiency_V3_1.mp4?time=1652891374
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/thumbnail_XuefengGuo.jpg?time=1652891374,https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/XuefengGuo_LanguageProficiency_V3_1.mp4?time=1652891374
english
(British)
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/MikeHodges_LanguageProficiency_V3_1.mp4?time=1652891374
farsi
(فارسی)
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2021/01/NedaSafarzadeh_LanguageProficiency_V4.mp4?time=1652891374
french
(Français)
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/NadjaEl-mecharrafie_LanguageProficiency_V3_1.mp4?time=1652891374
german
(deutsch)
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/LisaKieweg-Thompson_LanguageProficiency_V3_1.mp4?time=1652891374
hebrew
(עִברִית)
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/thumbnail_NoaScott.jpg?time=1652891374,https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/NoaScott_LanguageProficiency_V3_1.mp4?time=1652891374
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/thumbnail_TamarGrossman.jpg?time=1652891374,https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/TamarGrossman_LanguageProficiency_V3_1.mp4?time=1652891374
hindi
(हिन्दी)
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/PriyaKarmali_LanguageProficiency_V3_1.mp4?time=1652891374
italian
(italiano)
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/thumbnail_CristianoSacchetti.jpg?time=1652891374,https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/CristianoSacchetti_LanguageProficiency_V3_1.mp4?time=1652891374
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/thumbnail_GiulioCattarossi.jpg?time=1652891374,https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/GiulioCattarossi_LanguageProficiency_V3_1.mp4?time=1652891374
Japanese
(日本語)
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/09/Kiyoshi_Tachikawa_v2.mp4?time=1652891374
korean
(한국어)
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/JaeHeonKim_LanguageProficiency_V3_1.mp4?time=1652891374
portuguese
(Português)
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/RamonDiazTrelles_LanguageProficiency_V3_1.mp4?time=1652891374
spanish
(español)
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/CarlosPerezGarcia_LanguageProficiency__V3_1.mp4?time=1652891374
vietnamese
(Tiếng Việt)
https://secureservercdn.net/45.40.151.233/e32.83a.myftpupload.com/wp-content/uploads/2020/07/HannahHuynh_LanguageProficiency_V3_1.mp4?time=1652891374

News & Events

May 9, 2022
Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress
May 5, 2022
Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial
April 27, 2022
Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022
April 20, 2022
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
March 25, 2022
Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
February 28, 2022
Arcturus Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and Pipeline Progress
February 16, 2022
Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022
February 8, 2022
Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
January 25, 2022
Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial
January 24, 2022
Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants
December 16, 2021
Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials
December 13, 2021
Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors
November 22, 2021
Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference
November 18, 2021
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 8, 2021
Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress
October 25, 2021
Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021
October 21, 2021
Arcturus Therapeutics Announces Leadership Appointments
October 20, 2021
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 12, 2021
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
September 22, 2021
Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration

LUNAR® Mechanism of Delivery